Oral anticoagulation therapy increase the risk of SDH 4-to 15-fold.
hemorrhage, and intraventricular hemorrhage, are usually seen in the initial computed tomography (CT) scan.
Acute subdural hematomas are rarely reported in the literature. They are frequently due to injury at cerebral bridging veins secondary to head trauma. [13] ASDHs generally begin to be symptomatic within 72 h and usually occur in young adults.
Spontaneous ASDH is an unusual event, but it is a serious condition. The reported incidences of spontaneous ASDHs relative to total ASDHs have ranged from 2 to 6.7%. [14] [15] [16] Risk factors for the development of these hematomas include conditions such as hypertension, vascular abnormalities (such as aneurysm or arteriovenous malformation), or consumption of anticoagulant. [17] Pharmacologic therapy linked with the development of spontaneous ASDH includes especially aspirin, [14, 18] heparin, [14] and warfarin. [14, [19] [20] [21] Other reports of spontaneous ASDH mention risk factors such as coagulopathies related to coagulation factor deficiencies. [13, 22, 23] Mortality rate has been reported to be between 60% and 76.5%.
Introduction
Intracranial hemorrhage (ICH) accounts for approximately 10-15% of all cases of stroke, and it is associated with a high mortality rate. [1] Mild traumatic brain injury (TBI) often occurs in elderly patients, many of whom are treated with anticoagulants, which are known to increase the risk of bleeding events. [2, 3] Oral anticoagulation therapy (OAT) is associated with a high risk of ICH, even after minor head trauma. [2, [4] [5] [6] [7] [8] As a result, TBI patients with coagulopathy are included in a high-risk group regardless of clinical presentation. [5, [9] [10] [11] [12] The European Federation of Neurological Societies recommends that patients with a Glasgow coma scale (GCS) of 15 after mild TBI who are over 60 years of age or who are on anticoagulation, need to be admitted to the hospital for 24-h observation.
Posttraumatic ICHs, including epidural hematoma, subdural hematoma (SDH), subarachnoid hemorrhage, intracerebral Infusion of prothrombin complex concentrate appeared to reverse the coagulopathy more rapidly than fresh frozen plasma and was associated with improved outcome in one small study. [27] Early surgical intervention is generally imperative for hematomas with significant mass effect.
The survival rate for surgery within 4 h of acute onset compared with surgery after 4 h is 50-0%, respectively. [25] Other favorable variables include a high GCS score upon admission, appropriate pupillary reactivity, and young age. [25] We present two cases of ASDH in patients with the coagulation deficit:
• Female patient with a history of alcoholic cirrhosis • Male patient with a history of cardiac surgery in OAC.
The female patient, aged 59 arrived in an emergency room of our hospital at 9.30 a.m.
On admission to the hospital, the patient presented loss of consciousness, isocoria, midriasis and appropriate pupillary reactivity, decerebration extension at pain response, GCS 5 (E1, V1, M3).
Patient's husband referred a mild TBI after fall at 11.30 p.m. of the day before, history of alcoholic cirrhosis, HBV-and HCV-, with esophageal varix (Grade I), severe platelet deficiency in pancitopenia.
In an emergency room, the anesthesiologist stabilized the patient.
Patient underwent to the neuroimaging examination. CT scan showed acute subdural hematoma (ASDH) on left cerebral hemisphere with important midline structure shift, edema and indirect signs of ischemia [ Figure 1 ]. The patient was diagnosed with ASDH.
After diagnosis patient was treated with a liquid infusion, Vitamin K, Voluven and proton pump inhibitor drugs before neurosurgical operation.
Decompressive pterional craniotomy was performed, and SDH was removed [ Figure 2 ]. During the operation occurred hematemesis and melena. These events required hemotransfusion and endoscopic hemostasis of esophagogastric bleeding.
She was conducted in the resuscitation room, and she died 2 days later for cardiac arrest.
A male patient, 58-year-old, arrived in an emergency room of our hospital complaining an increasing headache, dizziness and vomiting. In the fourth hospitalization day his coagulation parameters were INR = 1.40, activated partial thromboplastin time (aPTT) =34.4 s., fibrinogen = 663 mg/dl, platelet = 114000/mm 3 . Because of consciousness falling, he retried a CT scan that showed an increase of the hematoma. For these reasons he was immediately treated with a neurosurgical operation.
Methodology
We report two cases of ASDH in uncoagulated patients:
• Female patient, 59-year-old, history of cirrhosis • Male patient, 58-year-old, history of mitral valve replacement.
A literature search using PubMed MEDLINE database has been performed. The search terms "nontraumatic ASDH," "spontaneous ASDH," were combined with the following terms: "Platelet deficit," "coagulation deficit."
Discussion
In this review of the literature, we compared the incidence of platelet deficiency with dysfunction of coagulation factors in ASDHs.
All conditions resulting in a low platelet count can predispose a patient to ICH. Thrombocytopenia has multiple causes, and one common classification scheme is as follows:
• Decreased platelet production, as seen in certain congenital disorders and cases of bone marrow damage (due to radiation, drugs) • Increased platelet destruction • Abnormal sequestration, usually in the spleen, as in cirrhosis • Multiple causes, as commonly seen in alcoholics.
Intracranial hemorrhage cases induced by thrombocytopenia have been linked to use of certain drugs, as well as to uremia, alcohol use, and liver transplants.
A large number of abnormalities of hemostasis were demonstrated in alcoholics patients.
Thrombocytopenia in these patients is due to associated folate deficiency, splenic sequestration and direct toxic effects of alcohol on the bone marrow. Numerous functional deficits have also been described in the platelets of alcoholics, which are associated with disturbances in ultrastructural morphology. [28] The largest study to date on alcohol use and ICH were conducted by the Honolulu Heart Program, which followed 8006 men between 1965 and 1977 in a prospective study of cardiovascular disease.
Data results further indicated that the alcohol had a greater effect on ICH that were subarachnoid in origin, conferring a 3-4-fold increased risk for moderate and heavy drinkers compared with nondrinkers. [29] No study was conducted to verify the incidence of ASDHs in alcoholics.
A lot of drugs have been associated with thrombocytopenia, including certain cytotoxic drugs, antimalarial agents, antiepileptic medications, furosemide, digoxin, and estrogens. [30] Any of these drugs could theoretically cause thrombocytopenia that could in turn contribute to ICH in a patient, especially one with other risk factors.
In a 1995 review, Hart, et al., suggested that anticoagulation to a "therapeutic" INR of 2.5-4.5 increases annual risk of ICH by 7-10-fold, to an absolute rate of nearly 1% for high-risk patient groups. Evaluation of individual large series shows great variation in the incidence of anticoagulation-treated patients in whom ICH is a complication, with annual incidences ranging from 0.1% in a 1974 study of 3862 patients to 2.2% in a 1993 study of 186 patients. [31] The most common antiplatelet agent in the world is aspirin. Aspirin works by irreversibly inactivating the enzyme cyclooxygenase, which results in decreased production of the natural platelet aggregate thromboxane A2. [32] The aspirin therapy is indicated for primary or secondary stroke prevention and primary myocardial infarction prevention, may slightly increase the low baseline risk of ICH, but the increased risk is usually outweighed by the benefits of aspirin.
Aspirin-related ICH has been studied in detail.
The first suggestion that increased incidence of ICH might be a complication in aspirin users is found in Physician's Health Study, which reported 23 hemorrhagic strokes among 11,037 individuals receiving low-dose aspirin (325 mg every other day) compared with 12 hemorrhagic strokes in 11,034 individuals receiving placebo. This finding was considered noteworthy but of borderline statistical significance (P = 0.06). [33] In addition to aspirin, other antiplatelet agents that have grown in popularity in recent years include clopidogrel, [34] abciximab, [35] as well as aspirin combined with extended-release dipyridamole. [36] Clopidogrel, abciximab, and dipyridamole all act as glycoprotein IIb/IIIa inhibitors in slightly different ways and have different indications [ Table 1 ].
In a small number of studies, the authors have examined the risk of ICH in patients receiving these newer antiplatelet agents.
The most comprehensive data are derived from a metaanalysis conducted by Memon et al., [37] in which the authors evaluated 14 randomized trials of intravenous platelet glycoprotein IIb/ IIIa receptor inhibitors. The results of the aforementioned metaanalysis, while suggesting that intravenous glycoprotein IIb/IIIa inhibitors did not increase the risk of ICH in anticoagulant-treated patients, failed to provide information on the incidence of hemorrhagic stroke in patients receiving oral formulations of the medications alone. The authors also compared glycoprotein IIb/IIIa inhibitors with a more commonly used antiplatelet agent: Aspirin.
Analysis of current data suggests that the newer antiplatelet agents discussed thus seem to be associated with an ICH risk profile similar to that of aspirin.
Warfarin, heparin, and enoxaparin are currently the most commonly used anticoagulants.
Warfarin is an OAC that interferes with vitamin K metabolism in the liver and results in the synthesis of nonfunctional coagulation factors II, VII, IX, and X, as well as proteins C and S.
Warfarin thus prolongs the PT and is monitored by assessing a standardized form of this test known as the INR.
Heparin, on the other hand, is a parenterally administered anticoagulant agent that acts by potentiating the action of both antithrombin III and tissue factor pathway inhibitor (TFPI), thus prolonging the PTT. [38] Enoxaparin is the most commonly used member of a relatively new class of anticoagulants known as low molecular weight heparins. It is obtained by alkaline degradation of heparin benzyl ester and is approximately one third the molecular size of standard heparin. The mechanism of action of enoxaparin is similar to that of heparin, although enoxaparin has a longer half-life (4.5 compared with 1.1 h) and does not require PTT monitoring. [39, 40] Anticoagulation-related bleeding is clinically similar for each of the aforementioned drugs and accounts for 10-20% of all ICHs in different series. [41] [42] [43] Furthermore, ICH is the most dreaded and least treatable complication of anticoagulation therapy. [44] Aspirin appears to double the risk for ICH, regardless of the dose. [45] The combination of aspirin with warfarin probably increases the risk for ICH over similar intensities of anticoagulation without aspirin (pooled data from four randomized trials of OACs show 15 ICHs with aspirin 100-1000 mg/d versus 7 without aspirin). [31] In the second Stroke Prevention in Atrial Fibrillation study, investigators showed that the occurrence of ICH actually negated the reduction in ischemic stroke among older hypertensive patients receiving warfarin. [46] Approximately, 70% of ICH episodes associated with anticoagulation consist of intraparenchymal (cerebral) hemorrhage, whereas most of the remainder are SDHs. [3] 
Conclusion
Coagulation and/or bleeding disorders account only for a small but significant risk factor associated with ICH. Blood coagulation and platelet-mediated hemostasis are the two important defense mechanisms against bleeding.
Anticoagulant mechanisms ensure careful control of coagulation and under normal conditions, prevail over the procoagulant forces. In the CNS, however, an imbalance between pro-and anticoagulant systems due to inherited or acquired factors may result in bleeding or thrombotic diseases.
Spontaneous ASDH is a nosological entity rare but extremely serious. In our view it would be appropriate to perform a series of study to understand the most appropriate medical therapy in the management of disease: Is more useful adjust platelet deficiency, coagulation factors disorder, or both? 
